NIEHS SBIR/STTR Grants Supporting NICEATM

Dan Shaughnessy, Lingamanaidu Ravichandran

NIEHS Division of Extramural Research and Training

NTP Board of Scientific Counselors

December 7-8, 2017

National Institutes of Health • U.S. Department of Health and Human Services

Overview

- Background
- Current Grants
- Current solicitations
 - Phase IIB for Approaches to Reduce Animal Use in Toxicity Testing (U44)
 - Re-release of Novel Assays for Screening the Effects of Chemical Toxicants on Cell Differentiation (SBIR R44 – Phase II only)
 - Organotypic Culture Models developed from Experimental Animals for Chemical Toxicity Screening (R43/R44)



SBIR = <u>S</u> mall <u>B</u> usiness <u>Innovation R</u> esearch	STTR = <u>S</u> mall Business <u>T</u> echnology <u>T</u> ransfe <u>r</u>
For Profit	 Minimum - For Profit (40%) + Nonprofit (30%)
• <500 employees	 <500 employees at For Profit
 US owned and operated 	US owned and operated

 11 Federal Agencies w/ extramural budgets >\$100M

FY	SBIR Required Allocations	NIEHS Budget
2015	2.90%	~\$12.6M
2016	3.00%	~\$13.6M
2017	3.20%	~\$15.1M
2018-2022	3.20%	

2017 - SRP ~\$1.7M and WTP ~\$740k

 5 Federal Agencies w/ extramural budgets >\$1B

FY	STTR Required Allocations	NIEHS Budget
2015	0.40%	~\$2.1M
2016	0.45%	~\$2.4M
2017	0.45%	~\$2.4M
2018-2022	0.45%	



PHASE I Feasibility Study (SBIR R43, STTR R41)

- Budget Guide: Up to \$150K Total Costs
- Project Period: 6 months (SBIR); 1 year (STTR)

PHASE II Full Research/R&D (SBIR R44, STTR R42)

Up to \$1M Total Costs over 2 years

PHASE IIB Competing Renewal/R&D

- Clinical R&D; Complex Instrumentation/Tools to FDA
- Many, but not all, ICs participate
- Varies ~\$1M/year for 3 years



PHASE III Commercialization Stage

- NIH, generally, not the "customer"
- Consider partnering and exit strategy early

NIEHS SBIR/STTR Programs

Emphasis on development of novel approaches using state-of-the-art technologies for environmental health sciences.

Exposure Assessment Tools	Integrated systems or models combining sensor, biomonitoring technology, and existing databases		
Nano Env. Health/Safety	Sensors, biomonitoring technology, and in vitro assays		
Toxicity Screening, Testing, and Modeling	Improved or expanded methods with multiple endpoints, incorporation of genetic diversity, and reduction of animal use		
Biomarkers	Oxidative stress, inflammation, DNA damage, immune function, mitochondrial function, and epigenetic regulation		
Education and Outreach	Tools that improve environmental health literacy, promote understanding of EHS, and support citizen science endeavors		
Superfund Research Program	Detection and/or remediation technologies		



Unsolicited SBIR/STTR Grants

Grant Number	PI	Institution	Title	Technology Category
R43 ES027711-01	Clewell, Rebecca	Scitovation, LLC	Development of high sensitivity in vitro assay to detect DNA double strand breaks	Cell-based Toxicity Assay
R43 ES027375-01	Mcclelland, Randall	Scikon Innovation, Inc.	Microfluidic Biotool to Accurately Model Corrosive Chemical Exposures for Human	Cell-based Toxicity Assay
R43 ES027703-01	Herron, Todd	Cartox, LLC	Functionally Mature Human Stem Cell Derived Cardiac Monolayers for Cardiotoxicity Testing	Cell-based Toxicity Assay
R43 ES028654-01	Choi, Ted	Predictive Biology	Novel Single Cell Assay to Identify Genes Underlying Developmental Neurotoxicity	Cell-based Toxicity Assay
R43 ES025501-01	Lebrun, Stewart	Lebrun Labs, LLC	Non-Animal Test Method To Determine The Ocular Safety Of Consumer Products and Chemicals	Cell-based Toxicity Assay
R44 ES024052-02	DeGeorge, George	MB Research Laboratories	Integrated In Vitro and Alternative Ocular (IIVAO) Irritation Testing Strategy	Cell-based Toxicity Assay
R44 ES02464402	Souza, Glauco	Nano3DBiosciences, Inc	Development of high-throughput cardiotoxicity and hepatotoxicity assays with magnetic 3D bioprinting	Organotypic model for Tox Testing
R43 ES027374-01	Yin, Lei	Reprotox Biotech	Innovative three-dimensional testicular Co- culture (Mini-Testis) model for reproductive toxicity testing: a pathway based High throughput (HT) and High Content Analysis (HCA)	Organotypic model for Tox Testing

NIEHS SBIR/STTR Solicitations

- RFA-ES-15-016: NIEHS SBIR Phase IIB Awards for Validation and Commercialization of Approaches to Reduce Animal Use in Toxicology Testing (U44)
- RFA-ES-17-007: Novel Assays for Screening the Effects of Chemical Toxicants on Cell Differentiation (SBIR R44)
- **RFA-ES-17-008**: Organotypic Culture Models developed from Experimental Animals for Chemical Toxicity Screening



NIEHS SBIR Phase IIB Awards: Validation and Commercialization of Approaches to Reduce Animal Use in Toxicology Testing (U44)

- Supports efforts to accelerate acceptance & commercialization of alternative methods & approaches
- Grantees work through SC and ICCVAM/NICEATM to address validation needed for acceptance by
 - U.S. federal agencies

RFA-ES-15-016 Applications due: Nov 13, 2017 Review: March 2018 (Dr. Leroy Worth)

- Approaches: In vitro assays, QSAR, and computational methods to predict toxicity
- Priority areas: Ocular toxicity, developmental toxicity, carcinogenicity, and acute toxicity testing
- Example: Validation of an In Vitro Human Airway Model for Regulatory Toxicity Testing (2U44ES014312-04 – Patrick Hayden, MatTek Corp.)






Validation of an In Vitro Human Airway Model for Regulatory Toxicity Testing

- Formal validation of the EpiAirway[™] in vitro human bronchial tissue model for predicting toxicity of inhaled chemicals
- Expanded number of test chemicals to verify the accuracy and relevance of the final prediction model
- Multi-laboratory GLP ring trial to establish the transferability, reproducibility, accuracy and relevance of the tissue model
- Final report and submission of test data to US federal regulatory agencies and OECD

The EpiAirway Model

EpiAirway is an *in vitro* 3D organotypic model of human tracheal/bronchial tissue.

- Constructed from primary cells
- Highly reproducible
- Differentiated epithelium at the air-liquid interface
 - Beating cilia
 - Mucus secretion
 - Barrier function
- Physiologically relevant & predictive of the human outcome






Regulatory systems for classifying the acute inhalation toxicity of chemicals

Environmental Protection Agency (EPA)				
Category I	Category II	Category I	Category IV	
	No Pictogram	No Pictogram	NoPictogram Caution	
Danger - Poison	Warning	Caution	(Optional)	
Fatal if inhaled	Maybe fatal if inhaled	Harm ful if in haled		


Occupational Safety & Health Administration (OSHA) Globally Harmonized System (GHS)					
Category 1	Category 2	Category 3	Category 3 Respiratory System	Category 4	Category 5
\diamond			(!)	()	No pictogram
Danger 330 Fatalif inhaled	Danger 330 Fatal if inhaled	Danger 331 Toxic if inhaled	Danger 335 May cause respiratory irritation	Warning 332 Harmful if inhaled	Warn ing 333 Maybe harm fulif in haled



Classification of EPA categories: In vivo rat vs. the EpiAirway test



Based on rat in vivo





NIH

National Institute of Environmental Health Sciences Your Environment. Your Health.

Novel Assays for Screening the Effects of Chemical Toxicants on Cell Differentiation (SBIR R44 – Phase II only)

Approaches can include:

- Assays evaluating alteration of ES/iPS cell differentiation
- Human iPS or mouse ES/iPS to incorporate genetic variation into toxicity screening
- Engineered stem cell lines to simulate common genetic variants in human disease (Parkinson's Disease, autism, breast cancer, etc.)
- High-content screening or 'omics-based assays for toxicant-induced effects using differentiated cell types derived from pluripotent or multi-potent cells

RFA-ES-17-007

Applications due: Oct 4, 2017 Review: Dec 2017 (Dr. Leroy Worth)



Organotypic Culture Models developed from Experimental Animals for Chemical Toxicity Screening (R43/R44)

- Develop 3D or organotypic models using cells derived from experimental animals typically used in toxicology testing
- Derived from ES or pluripotent cells, or single of multiple cell types to replicate target organ function with respect to toxicity

RFA-ES-17-008 Applications due: Jan. 12, 2018 Review: June 2018 (Dr. Leroy Worth)

- Allows comparisons between in vivo and in vitro test results
- Concordance between in vivo and in vitro test results will improve confidence in the utility of the in vitro models (both animal and human)
- · In vitro models will help to reduce the need for animals in tox testing



Questions?

National Institutes of Health • U.S. Department of Health and Human Services